详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience.

84| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China. [2]Orthopedic Oncology, Xijing Hospital Air Force Medical University of PLA (The Fourth Military Medical University), Xi'an, China. [3]Medical Oncology, Shanghai Sixth People's Hospital, Shanghai, China. [4]Orthopedic Oncology, Qilu Hospital of Shandong University, Jinan, China. [5]Musculoskeletal Tumor Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. [6]Orthopedic Oncology, Shanghai Changzheng Hospital, Shanghai, China. [7]Orthopedic Oncology, Jinan Military General Hospital, Jinan, China. [8]Orthopedic Oncology, Ruijin Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China. [9]Orthopedic Oncology, Shanghai General Hospital, Shanghai, China. [10]Orthopedic Oncology and Medical Oncology, Wuhan Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China. [11]Medical Oncology, The First Affiliated Hospital of Jilin University, Changchun, China. [12]Orthopedic Oncology, General Hospital of Eastern Theater Command, Nanjing, China. [13]Orthopedic Oncology, Huaxi Hospital West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), Chengdu, China. [14]Musculoskeletal Tumor Center, Liaoning Cancer Hospital & Institute, Shenyang, China.

出处：

DOI：

ISSN：

关键词： apatinib toxicity prophylaxis treatment osteosarcoma

摘要：

Four prospective trials have reported apatinib-related efficacy in osteosarcoma, with a high response rate of 43.2%. Currently, Adverse Events (AEs) have increasingly gained attention, as treatment with multiple tyrosine kinase inhibitors (TKIs) is potentially lifelong. For this reason, a consensus meeting of the Chinese Sarcoma Study Group (CSSG), which is a multidisciplinary panel composed of pediatric, medical and surgical oncologists specializing in sarcoma, nurse specialists, oncological senior pharmacists and gastroenterologists, was held to develop comprehensive guidelines on AEs emerging due to apatinib treatment to better assist in the prevention, management, and understanding of AE development. We summarized all AEs that arose in ≥10% of the participants as well as rare AEs that required extra caution to prevent that were observed in these four published prospective trials and arranged these AEs into 14 disorder systems according to CTCAE 5.0. In this review, we discuss strategies for the management of AEs in patients with advanced osteosarcoma, with the aim of maximizing treatment benefits and minimizing the need for apatinib treatment discontinuation. We also focus on providing recommendations for the prophylaxis and treatment of advanced osteosarcoma using apatinib to achieve optimal outcomes.Copyright © 2021 Xie, Xu, Guo, Wang, Yao, Li, Lin, Xiao, Yu, Zhang, Cai, Hua, Chen, Shao, Wu, Wu, Tu and Zhang.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

JCR分区：

出版当年[2021]版：

Q2 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3.5 最新[2023版] 4 最新五年平均 5.738 出版当年[2021版] 6.122 出版当年五年平均 6.244 出版前一年[2020版] 4.7 出版后一年[2022版]

第一作者：

第一作者机构： [1]Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series [2]Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC [3]Bronchial artery chemoembolization with apatinib for treatment of central lung squamous cell carcinoma [4]Apatinib treatment of advanced hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombus A case report [5]Ⅳ期寡转移NSCLC同期放化疗后巩固化疗前瞻性Ⅱ期临床研究 [6]DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma [7]Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer [8]Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC [9]ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib [10]3D-Printed Multifunctional Polyetheretherketone Bone Scaffold for Multimodal Treatment of Osteosarcoma and Osteomyelitis.